Amrize Expands Into Dallas-Fort Worth With Rapid Redi-Mix Acquisition as Evolus Prepares Q2 Results

The Quick Take

• Amrize completed acquisition of Rapid Redi-Mix, expanding its US ready-mix concrete network into the high-growth Dallas-Fort Worth metropolitan area
• DFW is among the fastest-growing US construction markets, adding 1.3M residents since 2020, making it a strategic priority for aggregates and concrete operators
• Evolus will report Q2 2026 results on August 5, with Jeuveau market share versus Botox the primary commercial metric to monitor in the aesthetics market

German-listed construction materials group Amrize confirmed completion of its acquisition of Rapid Redi-Mix, a Texas-based ready-mix concrete and aggregates supplier operating in the Dallas-Fort Worth metropolitan area — one of the fastest-growing construction markets in the United States. The transaction extends Amrize's existing US aggregates and concrete network into a strategically high-priority geography: DFW added over 1.3 million residents between 2020 and 2025, driving sustained residential and commercial construction demand that has outpaced national averages. For Amrize, integrating a local market participant with established contractor relationships and concrete batch plant infrastructure provides immediate revenue contribution without the lead time of greenfield capacity build.

The DFW acquisition signals Amrize's commitment to building a self-reinforcing US market presence through bolt-on acquisitions in high-growth metropolitan areas — a consolidation playbook with strong precedent in the North American aggregates sector, where Martin Marietta and Vulcan Materials have demonstrated that geographic density in growing metro markets generates durable pricing power and route efficiency advantages over regional competitors. The Dallas-Fort Worth construction market benefits from continued population migration from California, New York, and Illinois driven by lower state tax burdens and business-friendly regulation, a structural demand driver with multi-year visibility. Amrize's Q2 results, scheduled for August 6, will be the first readout confirming the Rapid Redi-Mix acquisition's initial contribution to group financials.

Separately, Evolus — a US pharmaceutical aesthetics company whose flagship product Jeuveau competes directly with AbbVie's market-leading Botox in the botulinum toxin space — will report Q2 2026 results on August 5. The aesthetics injectable market has proven surprisingly resilient through interest rate cycles, as the mid-to-premium consumer target demographic maintains discretionary spending on recurring aesthetic procedures even during broader consumer softness. Watch Evolus's market share gains in medical aesthetics practices and any commentary on Jeuveau pricing relative to Botox — the competitive spread between Jeuveau and Botox pricing is the key commercial lever that Evolus management has used to drive practice adoption. Both August earnings calls represent the most significant near-term catalysts for these two distinct German-investor-tracked names.

Synthesized from 2 sources.